Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1990 1
2002 1
2003 1
2006 1
2012 2
2013 2
2015 2
2016 2
2017 4
2018 3
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

23 results
Results by year
Filters applied: . Clear all
Page 1
A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity.
Compte M, Harwood SL, Muñoz IG, Navarro R, Zonca M, Perez-Chacon G, Erce-Llamazares A, Merino N, Tapia-Galisteo A, Cuesta AM, Mikkelsen K, Caleiras E, Nuñez-Prado N, Aznar MA, Lykkemark S, Martínez-Torrecuadrada J, Melero I, Blanco FJ, Bernardino de la Serna J, Zapata JM, Sanz L, Alvarez-Vallina L. Compte M, et al. Among authors: harwood sl. Nat Commun. 2018 Nov 15;9(1):4809. doi: 10.1038/s41467-018-07195-w. Nat Commun. 2018. PMID: 30442944 Free PMC article.
Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies.
Mikkelsen K, Harwood SL, Compte M, Merino N, Mølgaard K, Lykkemark S, Alvarez-Mendez A, Blanco FJ, Álvarez-Vallina L. Mikkelsen K, et al. Among authors: harwood sl. Front Immunol. 2019 Jul 31;10:1791. doi: 10.3389/fimmu.2019.01791. eCollection 2019. Front Immunol. 2019. PMID: 31417564 Free PMC article.
We have recently generated an EGFR-targeted 4-1BB-agonistic trimerbody that demonstrated strong antitumor activity and did not induce systemic inflammatory cytokine secretion and hepatotoxicity associated with first-generation 4-1BB agonists. ...
We have recently generated an EGFR-targeted 4-1BB-agonistic trimerbody that demonstrated strong antitumor activity and did not induce system …
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, Compte M, Hernández-Pérez S, Merino N, Bonet J, Navarro R, Van Bergen En Henegouwen PMP, Lykkemark S, Mikkelsen K, Mølgaard K, Jabs F, Sanz L, Blanco FJ, Roda-Navarro P, Alvarez-Vallina L. Harwood SL, et al. Oncoimmunology. 2017 Sep 27;7(1):e1377874. doi: 10.1080/2162402X.2017.1377874. eCollection 2017. Oncoimmunology. 2017. PMID: 29296540 Free PMC article.
Lack of Suppression of Aldosterone Production Leads to Salt-Sensitive Hypertension in Female but Not Male Balb/C Mice.
Faulkner JL, Harwood D, Bender L, Shrestha L, Brands MW, Morwitzer MJ, Kennard S, Antonova G, Belin de Chantemèle EJ. Faulkner JL, et al. Hypertension. 2018 Dec;72(6):1397-1406. doi: 10.1161/HYPERTENSIONAHA.118.11303. Hypertension. 2018. PMID: 30571230 Free PMC article.
Females on an HS diet displayed no apparent increases in sodium retention as assessed by 24-hour urine collection, sodium balance measure, and saline loading excretion analysis. ...
Females on an HS diet displayed no apparent increases in sodium retention as assessed by 24-hour urine collection, sodium balance mea …
The coming of age of engineered multivalent antibodies.
Nuñez-Prado N, Compte M, Harwood S, Álvarez-Méndez A, Lykkemark S, Sanz L, Álvarez-Vallina L. Nuñez-Prado N, et al. Among authors: harwood s. Drug Discov Today. 2015 May;20(5):588-94. doi: 10.1016/j.drudis.2015.02.013. Epub 2015 Mar 7. Drug Discov Today. 2015. PMID: 25757598 Review.
Efficacy and toxicity management of CAR-T-cell immunotherapy: a matter of responsiveness control or tumour-specificity?
Alonso-Camino V, Harwood SL, Álvarez-Méndez A, Alvarez-Vallina L. Alonso-Camino V, et al. Among authors: harwood sl. Biochem Soc Trans. 2016 Apr 15;44(2):406-11. doi: 10.1042/BST20150286. Biochem Soc Trans. 2016. PMID: 27068947 Review.
Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.
Mølgaard K, Harwood SL, Compte M, Merino N, Bonet J, Alvarez-Cienfuegos A, Mikkelsen K, Nuñez-Prado N, Alvarez-Mendez A, Sanz L, Blanco FJ, Alvarez-Vallina L. Mølgaard K, et al. Among authors: harwood sl. Cancer Immunol Immunother. 2018 Aug;67(8):1251-1260. doi: 10.1007/s00262-018-2181-5. Epub 2018 Jun 4. Cancer Immunol Immunother. 2018. PMID: 29869168
The recruitment of T-cells by bispecific antibodies secreted from adoptively transferred, gene-modified autologous cells has shown satisfactory results in preclinical cancer models. ...In situ secreted LiTEs bound the cognate antigens of both parental antibodies and …
The recruitment of T-cells by bispecific antibodies secreted from adoptively transferred, gene-modified autologous cells has shown sa …
Balanced secretion of anti-CEA × anti-CD3 diabody chains using the 2A self-cleaving peptide maximizes diabody assembly and tumor-specific cytotoxicity.
Mølgaard K, Compte M, Nuñez-Prado N, Harwood SL, Sanz L, Alvarez-Vallina L. Mølgaard K, et al. Gene Ther. 2017 Apr;24(4):208-214. doi: 10.1038/gt.2017.3. Epub 2017 Jan 11. Gene Ther. 2017. PMID: 28075428 Free PMC article.
Adoptive transfer of genetically engineered human cells secreting bispecific T-cell engagers has shown encouraging therapeutic effects in preclinical models of cancer. ...
Adoptive transfer of genetically engineered human cells secreting bispecific T-cell engagers has shown encouraging therapeutic effect …
Cell polarity and Dictyostelium development.
Williams HP, Harwood AJ. Williams HP, et al. Curr Opin Microbiol. 2003 Dec;6(6):621-7. doi: 10.1016/j.mib.2003.10.008. Curr Opin Microbiol. 2003. PMID: 14662359 Review.
This involves a balance between local induction of F-actin polymerization and suppression of pseudopods that point in other directions. ...Finally, cells polarize secretion to particular regions of their surface....
This involves a balance between local induction of F-actin polymerization and suppression of pseudopods that point in other direction …
A systematic review of muscle morphology and function in intermittent claudication.
Harwood AE, King S, Totty J, Smith GE, Vanicek N, Chetter IC. Harwood AE, et al. J Vasc Surg. 2017 Oct;66(4):1241-1257. doi: 10.1016/j.jvs.2017.05.106. Epub 2017 Aug 16. J Vasc Surg. 2017. PMID: 28822657 Review.
OBJECTIVE: Intermittent claudication (IC) is frequently associated with deterioration in walking capacity and physical function, and it can often result in an impairment in balance. ...Seven papers reported on muscle metabolism, incorporating adenosine diphosphate r …
OBJECTIVE: Intermittent claudication (IC) is frequently associated with deterioration in walking capacity and physical function, and it can …
23 results
Jump to page
Feedback